HC Wainwright & Co. Initiates Coverage On Ascendis Pharma with Buy Rating, Announces Price Target of $345

Benzinga Newsdesk www.benzinga.com Neutral 58.0%

Neg 0% Neu 58% Pos 0%

HC Wainwright & Co. analyst Mitchell S. Kapoor initiates coverage on Ascendis Pharma (NASDAQ:ASND) with a Buy rating and announces Price Target of $345.